Shasqi, Inc
Shasqi is a biotech company focused on making cancer drugs more effective through innovative click chemistry technology. Their proprietary CAPAC platform enables targeted activation of therapeutics at tumor sites, reducing systemic toxicity and expanding treatment possibilities. They are advancing a diverse pipeline of tumor-targeting agents and payloads, validated in clinical studies, with a mission to improve cancer treatment outcomes.
Industries
Nr. of Employees
small (1-50)
Shasqi, Inc
Products
Intratumoral biopolymer activator paired with systemically administered protodrugs
A therapeutic approach combining a locally delivered biopolymer activator that presents click-reactive groups at the tumor and a systemically dosed chemically attenuated protodrug that is activated on-site via in vivo click chemistry.
Systemically delivered protodrug payloads for multiple modalities
Protodrug constructs designed for chemotherapeutics, highly toxic cytotoxins, immune agonists and radiotherapeutic payloads that remain inactive in circulation until clicked at the tumor-localized activator.
Intratumoral biopolymer activator paired with systemically administered protodrugs
A therapeutic approach combining a locally delivered biopolymer activator that presents click-reactive groups at the tumor and a systemically dosed chemically attenuated protodrug that is activated on-site via in vivo click chemistry.
Systemically delivered protodrug payloads for multiple modalities
Protodrug constructs designed for chemotherapeutics, highly toxic cytotoxins, immune agonists and radiotherapeutic payloads that remain inactive in circulation until clicked at the tumor-localized activator.
Services
Research collaborations for pre-targeted therapeutics
Collaborative research and development partnerships to apply in vivo click chemistry pre-targeting to external antigen targets and payloads, including co-development of activators and protodrugs.
Preclinical and translational development services
Preclinical program execution including protodrug synthesis, activator design, animal efficacy and tolerability studies, PK/BD analysis, and immune response assessment to support clinical translation.
Research collaborations for pre-targeted therapeutics
Collaborative research and development partnerships to apply in vivo click chemistry pre-targeting to external antigen targets and payloads, including co-development of activators and protodrugs.
Preclinical and translational development services
Preclinical program execution including protodrug synthesis, activator design, animal efficacy and tolerability studies, PK/BD analysis, and immune response assessment to support clinical translation.
Expertise Areas
- Pre-targeting oncology therapeutics
- In vivo bioorthogonal (click) chemistry
- Protodrug (prodrug) design and medicinal chemistry
- Tumor-targeting activator engineering (antibodies, fragments, peptides, VHH)
Key Technologies
- In vivo click chemistry (bioorthogonal reactions)
- Chemical protodrug design and attenuation
- Injectable biopolymer activators (hyaluronate derivatives)
- Antibody- and peptide-based targeting agents